We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Advanced Oncotherapy Plc | LSE:AVO | London | Ordinary Share | GB00BD6SX109 | ORD 25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.925 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 0 | -29.49M | -0.0549 | -0.35 | 10.32M |
TIDMAVO
RNS Number : 2937K
Advanced Oncotherapy PLC
31 August 2021
31 August 2021
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Result of GM, TVR and clarification re warrants
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that at the General Meeting held earlier today, all resolutions were passed.
Accordingly, the 88,854,641 new Ordinary shares in respect of the Subscription and fee arrangements, details of which were set out in the Company's announcement of 11 August 2021, will be issued and are expected to be admitted to trading on AIM on 3 September 2021. The remaining 11,145,405 Subscription Shares are expected to be admitted to trading on AIM on or around 1 October 2021.
The results of the proxy voting for the General Meeting are set out below:
Resolution Total votes % of votes Total Votes % of votes Votes Withheld(3) For(1) cast(2) Against cast(2) 1 120,246,315 99.77 273,099 0.23 0 ------------ ----------- ------------ ----------- ------------------ 2 120,459,943 99.95 59,471 0.05 0 ------------ ----------- ------------ ----------- ------------------
Notes
1. Any proxy votes that were at the discretion of the Chairman are included in the "Total Votes For" each resolution
2. Percentage of votes cast excludes Votes Withheld
3. Votes Withheld are not votes in law and do not count in the number of votes counted for or against a resolution
Clarification regarding warrants
The following table summarises the warrants that remain in issue. The details in the table below are in accordance with the previous announcements made by the Company, although the dates of two outstanding batches of warrants have been incorrectly reflected in the last annual report due to a typographical error.
Issue Date Final date of exercise Exercise price Number of Warrants ------------ ------------------------ --------------- ------------------- 20-Jul-17 19-Jul-22 25p 20,468,687 26-Apr-18 25-Apr-23 70p 1,000,000 31-May-18 11-Jun-22 50p 450,000 31-Aug-18 31-Aug-23 100p 2,617,312 07-May-19 07-May-24 100p 3,500,000 31-Oct-19 31-Aug-24 100p 385,000 28-Jun-20 28-Jun-25 50p 5,000,000 Total 33,420,999 -------------------------------------- --------------- -------------------
Further warrants are due to be granted in respect of the Subscription on the dates falling six months after First Admission and Second Admission, as detailed in the Company's announcement of 11 August 2021.
Total voting rights
The Company's issued share capital as at the date of this announcement comprises 350,334,730 ordinary shares of 25p each, with one voting right per share ("Ordinary Shares"). The Company does not hold any ordinary shares in treasury and therefore the total number of Ordinary Shares with voting rights in the Company is 350,334,730.
On 3 September 2021, a further 88,854,641 Ordinary Shares will be issued as detailed above. Therefore, from 3 September 2021 the issued share capital of the Company will comprise 439,189,371 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury and therefore the total voting rights in the Company will be 439,189,371. From 3 September 2021, the figure of 439,189,371 should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Defined terms used in this announcement shall have the same meaning as in the announcement of 11 August 2021 unless otherwise defined herein.
- ENDS -
Notes for editors
Advanced Oncotherapy plc www.avoplc.com Dr. Michael Sinclair, Executive Chairman Tel: +44 (0) 20 3617 8728 Nicolas Serandour, CEO Allenby Capital Limited (Nomad and Joint Broker) Nick Athanas / Liz Kirchner (Corporate Finance) Tel: +44 (0) 20 3328 5656 Amrit Nahal / Matt Butlin (Sales and Corporate Broking) SI Capital Ltd (Joint Broker) Nick Emerson Tel: +44 (0) 1483 413 500 Jon Levinson Tel: +44 (0) 20 3871 4066 FTI Consulting (Financial PR & IR) advancedoncotherapy@fticonsulting.com Simon Conway / Rob Winder Tel: +44 (0) 20 3727 1000
About Advanced Oncotherapy Plc
Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCMZGFRNMGGMZM
(END) Dow Jones Newswires
August 31, 2021 13:14 ET (17:14 GMT)
1 Year Advanced Oncotherapy Chart |
1 Month Advanced Oncotherapy Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions